Navigation Links
Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop

-- More than 70 abstracts highlight VELCADE efficacy in broad range of patients and across continuum of care --

CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that data for VELCADE, the market leading therapy with unsurpassed single-agent efficacy for patients with previously treated multiple myeloma (MM), will be featured at the upcoming International Myeloma Workshop (IMW) in Kos, Greece, June 25-30, 2007.

"Clinical data to be presented next week will underscore the crucial role of VELCADE based therapies in the front-line multiple myeloma treatment setting. These results will show that the high complete response rates seen with VELCADE based combinations translate to some of the most impressive survival rates to date," said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. "These are exciting data for the field of multiple myeloma as we see that combining the power of VELCADE with other active agents substantially prolonged the lives of patients."

VELCADE in Front-Line MM Patients

Previously presented data have shown that VELCADE based combinations produce very high complete and near complete response rates. Data presented at this conference are expected to provide further evidence that this benefit leads to prolonged survival. Abstract highlights include:

    -- Phase I / II Study of Upfront VELCADE, Lenalidomide and Dexamethasone

       in Multiple Myeloma: Early Results

         * Lead investigator: Paul Richardson, M.D., Dana-Farber Cancer

           Institute

         * Abstract #715; Poster session: Thursday 28th June, 4:30 p.m.

    -- Front-line VELCADE, Melphalan and Prednisone (VMP) in Elderly Multiple

       Myeloma Patients: Extended Follow-Up

         * Lead investigator: Maria-Victoria Mateos, M.D., PhD., Grupo Espanol

           de Multiple Myeloma

         * Abstract #718
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:8/27/2015)... INDIANAPOLIS , Aug. 27, 2015  Eli Lilly ... Morgan Stanley Global Healthcare Conference on Thursday, September 17, ... and president of Lilly Oncology and Richard Gaynor ... medical affairs for Lilly Oncology, will participate in a ... A live audio webcast will be available ...
(Date:8/27/2015)... Ohio , Aug. 27, 2015  A mere ... to Booz Allen Hamilton . A new ... product development inefficiencies are impeding and disrupting manufacturers, success. ... Cut Waste and Improve Value In Product Development Processes ... of inaccessible data and how it affects the product ...
(Date:8/27/2015)... and TORONTO , Aug. ... (OTCQB: GNBT) today announced the issuance of a white ... proprietary buccal insulin spray product.  The white paper was ... the Company,s stockholders by Dr. James H. Anderson, ... white paper may be viewed online on the Generex ...
Breaking Medicine Technology:Lilly to Participate in Morgan Stanley Global Healthcare Conference 2New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4
... CYBX ), a global leader in epilepsy management, today ... Sciences Conference on Wednesday, September 21, 2011, in New York. ... will speak to the attendees of the conference 10:00 AM ... be accessed by clicking on the Investor Relations link on ...
... 7, 2011 Generex Biotechnology Corporation ( www.generex.com ... the Company,s President & Chief Executive Officer, and ... wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ) ... & Renshaw 13th Annual Healthcare Conference.  The presentation ...
Cached Medicine Technology:Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 2Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 3
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Susan ... edge procedure to relieve vaginal discomfort due to pre- and post-menopause, chemotherapy, and child ... a CO2 laser, which delivers controlled energy to the vaginal tissue, revitalizing cells so ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since its launch ... to having twelve offices in three counties, LA, Orange and San Bernardino. ... region. Founded by Dr. Richy Agajanian, the Oncology Institute of Hope and ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... California including Los Angeles, Riverside, San Bernardino, and Orange County. , ... executive physical exams are offered annually at all of its locations. Executive ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... today that they have launched their new corporate website http://www.Z-Medica.com , to ... a product-focused website that was launched last year. , “We launched a ...
(Date:8/27/2015)... Newport Beach, CA (PRWEB) , ... August 27, ... ... services and products, announced today that the new issue of Chairside® magazine, its ... the latest issue, Volume 10, Issue 3, as well as past issues of ...
Breaking Medicine News(10 mins):Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2Health News:Healthpointe Now Offering Executive Physicals 2Health News:Z-Medica® Launches New Corporate Website 2Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 2Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 3
... Administration (FDA) approved a gel that promises less ... FDA had initially rejected Lifecore Biomedical Inc.'s Intergel, ... gynecologic operations. // ,The gel, formally ... to reduce adhesions, internal scar tissue that can ...
... protein released by damaged heart tissue may be a helpful ... Performing heart bypass surgery or angioplasty on patients with elevated ... estimated 40 percent. ,// ,"Any sign of heart ... amount, was a sign that the patient was at high ...
... it shows that warfarin and aspirin are equally effective in ... prevents blood clotting by stopping platelets from clumping together, while ... both are known to help prevent blood clots in the ... thought that warfarin is more effective at preventing stroke, but ...
... has a similar impact on the body to the ... chronic disorders such as heart disease and diabetes, researchers ... people spend asleep per night in more developed countries ... change has been made to accommodate increased demands of ...
... time, the US Food and Drug Administration (FDA) has approved ... by New Jersey-based Johnson & Johnson, is a one-and-three-quarter-inch patch ... an alternative to birth control pills. // ,The ... period. Ortho Evra can be worn on the lower abdomen, ...
... found a way of creating brain cells out of bone ... Parkinson's disease. At the Peterson Medical College scientists grew stem ... growth factors and other chemicals and found they could get ... cells form muscle, bone, cartilage and fat. The researchers say ...
Cached Medicine News:Health News:Deprived sleep leads to ageing 2
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... can operate in two additional modes. The ... creating a fully featured handheld pulse oximeter, ... used to upgrade existing equipment through the ... or software upgrades to improve the performance ...
... The stylish Avant® 9600s simple functionality, ... of memory makes it well-suited for ... proven digital pulse oximetry, the Avant ... rugged durability. The 9600 provides a ...
Medicine Products: